학술논문
Risk of strong antibody decline in dialysis and transplant patients after SARS-CoV-2mRNA vaccination: Six months data from the observational Dia-Vacc study
Document Type
article
Author
Julian Stumpf; Jörg Schwöbel; Tom Lindner; Leona Anders; Torsten Siepmann; Claudia Karger; Jan Hüther; Heike Martin; Petra Müller; Robert Faulhaber-Walter; Torsten Langer; Holger Schirutschke; Thomas Stehr; Frank Meistring; Annegret Pietzonka; Kirsten Anding-Rost; Katja Escher; Frank Pistrosch; Jens Schewe; Harald Seidel; Kerstin Barnett; Thilo Pluntke; Simon Cerny; Alexander Paliege; Ingolf Bast; Anne Steglich; Florian Gembardt; Friederike Kessel; Hannah Kröger; Patrick Arndt; Jan Sradnick; Kerstin Frank; Anna Klimova; René Mauer; Xina Grählert; Torsten Tonn; Christian Hugo
Source
The Lancet Regional Health. Europe, Vol 17, Iss , Pp 100371- (2022)
Subject
Language
English
ISSN
2666-7762
Abstract
Summary: Background: Vulnerable dialysis and kidney transplant patients show impaired seroconversion rates compared to medical personnel eight weeks after SARS-CoV-2mRNA vaccination. Methods: We evaluated six months follow up data in our observational Dia-Vacc study exploring specific cellular (interferon-γ release assay) or/and humoral immune responses after 2x SARS-CoV-2mRNA vaccination in 1205 participants including medical personnel (125 MP), dialysis patients (970 DP) and kidney transplant recipients (110 KTR) with seroconversion (de novo IgA or IgG antibody positivity by ELISA) after eight weeks. Findings: Six months after vaccination, seroconversion remained positive in 98% of MP, but 91%/87% of DP/KTR (p = 0·005), respectively. Receptor binding domain-IgG (RBD-IgG) antibodies were positive in 98% of MP, but only 68%/57% of DP/KTR (p